Other techniques he suggested include the use of anatomical or idealized inhaler inlets such as the throats available from Emmace Consulting and Copley Scientific. “Why are still using the USP right angle bend inlet?” he asked, encouraging developers to investigate use of the more relevant inlets.
Copley Scientific is exhibiting the new Child Alberta Idealised Throat
Copley is exhibiting the Child Alberta Idealised Throat for the first time at DDL 24.
After the conclusion of the lecture, DDL Committee member Yorick Kamlag joined Mitchell on stage to make a presentation of several gifts on behalf of the European Pharmaceutical Aerosol Group (EPAG), along with a slideshow titled “This is Your Life Jolyon Mitchell” in honor of his work with EPAG. Kamlag noted that over the course of his career, Mitchell has published on average approximately one paper per month.
The afternoon paper session, title “Aerosol nano-medicines: friend or foe?” featured three presentations: Terry Tetley of Imperial College London addressing the question “Are there lessons from Environmental Nanotoxicology?”; Sally Ann Cryan of the Royal College of Surgeons in Ireland asking “What do Inhaled Nanomedicines offer?”; and Fakhrul Ahsan of Texas Tech University describing “Aerosolized Targeted Nanoerythrosomes Containing Fasudil, a Rho-kinase Inhibitor, for the Treatment of Pulmonary Arterial Hypertension.”
Each of the speakers in the nano-medicine session received extra time after the day’s final presentation, titled “Clinical Pharmacology and Physiology of ageing: implications for Drug Therapy,” was canceled because presenter Stephen Jackson of King’s College London was unable to attend.
At the end of the first day of the meeting, attendees gathered in the exhibition area for a drinks reception sponsored by Vectura. Approximately 80 companies are exhibiting at this year’s meeting, 5 of them for the first time.
